The ER-PR Her2 test is a crucial diagnostic tool in the management of breast cancer.
This test evaluates three specific markers—estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (Her2)—to provide insights into the biology of a tumor. Understanding the results of this test is vital for determining the most effective treatment options and predicting patient outcomes.
What Are ER, PR, and Her2?
1] Estrogen Receptors (ER): These are proteins found in some breast cancer cells that bind to estrogen. The presence of ER indicates that the tumor may grow in response to estrogen. About 70% of breast cancers are ER-positive, meaning they can be treated with hormonal therapies that lower estrogen levels or block its action.
2]Progesterone Receptors (PR): Similar to estrogen receptors, PR are proteins that bind to the hormone progesterone. Tumors that are PR-positive may also respond to hormonal therapies. The presence of both ER and PR can suggest a more favorable prognosis.
3] Her2 (Human Epidermal Growth Factor Receptor 2): This is a protein that can promote the growth of cancer cells. About 15-20% of breast cancers are Her2-positive, which often indicates a more aggressive form of the disease. However, targeted therapies, such as trastuzumab (Herceptin), are effective against Her2-positive tumors.
The ER-PR-Her2 test is usually performed on a tumor sample obtained through a biopsy. Here’s how the process typically works:
1] Tumor Sampling: A biopsy is performed to collect tissue from the breast tumor. This can be done through fine needle aspiration, core needle biopsy, or surgical biopsy, depending on the tumor's size and location.
2] Laboratory Analysis: The collected tissue is sent to a best pathology lab test centre, where it undergoes testing for the presence of ER, PR, and Her2 proteins. This can be done using various techniques, including:
3] Immunohistochemistry (IHC): This is the most common method for detecting ER and PR. It involves applying antibodies that bind to the respective receptors in the tumor tissue. The results are scored based on the percentage of cancer cells staining positive for these receptors.
4] Fluorescence In Situ Hybridization (FISH): This method is often used to evaluate Her2 status. It involves using fluorescent probes that bind to specific parts of the Her2 gene to determine whether it is amplified in the cancer cells.
5] Result Interpretation: The pathologist will provide a report detailing the results of the ER, PR, and Her2 tests, which will be used by the oncologist to develop a treatment plan.
1] ER Status: Positive or negative. A positive ER result indicates the presence of estrogen receptors in the tumor cells.
2] PR Status: Positive or negative. A positive PR result indicates the presence of progesterone receptors.
3] Her2 Status:
A] Positive (3+ on IHC): Indicates a high level of Her2 protein overexpression or Her2 gene amplification.
B] Negative (0 or 1+ on IHC): Indicates low or no Her2 protein expression.
C] Equivocal (2+ on IHC): Requires further testing (usually FISH) to determine Her2 status.
At Diagnopein, we offer comprehensive, accurate, and timely diagnostic services, including the ER-PR Her2 test Pune. With our NABL-accredited labs, cutting-edge technology, and skilled technicians, you can be assured of reliable results every time. Get your results quickly, especially when time is crucial in detecting severe infections.
Competitive pricing without compromising on quality. Our team of experienced professionals ensures the test is conducted smoothly with minimal discomfort. We provide not just the ER-PR Her2 test results but insights into your health condition, helping you and your doctor make informed decisions about treatment. For more information call us at +91 9204 108108.
Yes, the test is standard for newly diagnosed breast cancer patients to inform treatment strategies and is typically performed on tumor tissue obtained during a biopsy.
The test is performed on a tumor sample obtained through a biopsy. The sample is analyzed in a lab using techniques like immunohistochemistry (IHC) for ER and PR and fluorescence in situ hybridization (FISH) for Her2.
The test provides critical information for personalized treatment plans, predicting how well a patient may respond to certain therapies, and offering prognostic information about the cancer's aggressiveness.
Biopsies are generally safe but may carry minor risks such as bleeding, infection, or discomfort at the site.
